Establishing five-year overall survival as a new standard for trials in advanced HCC

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-13 DOI:10.1016/j.jhep.2025.05.001

Pierre Nahon

引用次数: 0

Abstract

Section snippets

Disclosures

Pr Nahon has received honoraria from and/or consults for AstraZeneca, Bristol-Myers Squibb, Eisai, and Roche. He received research grants from AstraZeneca, Bristol-Myers Squibb and Eisai.

Grant Support

Pierre Nahon’s research is funded in part by the European Union (GENIAL, Grant agreement ID: 101096312), French Agence Nationale de la Recherche (France 2030 DELIVER ANR-21-RHUS-0001) and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014).

Declaration of Competing Interest

none to declare

查看原文本刊更多论文

建立5年总生存期作为晚期HCC临床试验的新标准

Nahon已经从阿斯利康、百时美施贵宝、卫材和罗氏获得了酬金和/或顾问。他获得了阿斯利康、百时美施贵宝和卫材的研究资助。pierre Nahon的研究部分由欧盟（资助协议ID: 101096312）、法国国家研究机构（France 2030 DELIVER ANR-21-RHUS-0001）和法国2030 RHU肝脏- track （ANR-23-RHUS-0014）资助。竞争利益声明无须申报

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.